NeuVasQ is developing pharmaceutical treatments to restore the blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, and in neurodegenerative disorders like Alzheimer’s disease.
Disruptive technology
NeuVasQ Biotechnologies, a spin-off from the Université Libre de Bruxelles (ULB), is developing pharmaceuticals to sustain or restore the neurovascular function, a novel mechanism to interfere with disease progression for the benefit of millions of patients affected by neurological disorders.
Our research and development programs selectively target the cells forming the blood-brain barrier (BBB), the structure that regulates exchanges between the vascular system and the central nervous system (CNS). BBB dysregulation, due to age or injury, has been associated with the leakage of harmful blood substances into the CNS. Restoring the BBB function may therefore help to treat neurodegenerative disorders such as Alzheimer’s disease, acute neurological conditions like stroke, and certain types of brain cancers.
Contact
Emmanuel LACROIX, CEO
Email: info@neuvasq.com
